NCT06693518View on ClinicalTrials.gov

A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions
SARS-CoV-2 Infections
Interventions
DRUG

Treatment B

Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg

DRUG

Treatment A

Dabigatran Etexilate 150 mg

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06693518 - A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults | Biotech Hunter | Biotech Hunter